Cargando…
Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
BACKGROUND: Metastatic or relapsed angiosarcoma has a poor prognosis and the efficacy of conventional chemotherapy is often limited. Apatinib, a novel tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor-2 (VEGFR2), has been approved for the treatment of advanced gas...
Autores principales: | Yang, Lishu, Liu, Lizhu, Han, Bo, Han, Wei, Zhao, Meng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984462/ https://www.ncbi.nlm.nih.gov/pubmed/29855279 http://dx.doi.org/10.1186/s12885-018-4523-2 |
Ejemplares similares
-
Successful treatment of angiosarcoma of the scalp with apatinib: a case report
por: Ji, Guanghui, et al.
Publicado: (2016) -
Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiation-induced abdominal wall angiosarcoma with low-dose apatinib: a case report
por: Guan, Jieshan, et al.
Publicado: (2019) -
Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy
por: Luo, Cong, et al.
Publicado: (2017) -
The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019) -
PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
por: Carlotto, Bianca Soares, et al.
Publicado: (2023)